Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spermidine Supplementation in Overweight or Obese Individuals With Hyperlipidemia
NCT07662330Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial in obesity and hyperlipidemia comparing Trial group (spermidine) with Control group (placebo) (2 arms). Primary endpoint: Triglycerides at 1 month. Started Jan 2026; status: recruiting.
02
Drugs
spermidine
03
Conditions
obesityhyperlipidemia
Beyond the preview
Go deeper on NCT07662330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662330.